Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

nd Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.  

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Research Inc., a Montreal based Contract Research ... Neeman International (MNI), with head office in New Delhi, ... Bangalore , Chennai and ... is located North Carolina, USA . ... transaction into JSS with Capital Croissance PME (CCPME), a joint fund ...
(Date:5/4/2015)... 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced ... Form 20-F for the fiscal year ended December 31, ... The annual report on Form 20-F contains information regarding ... the area of cancer immune checkpoints. This project aims ... specificity and binding in targeting certain identified immune checkpoints. ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... May 04, 2015 Achieved primarily through ... slides that boast 10 to 100x better detail than ... capabilities of all existing light microscopy methods, it needed ... were chosen as the frame of reference because it ... , The goal from the earliest discovery days of ...
Breaking Biology Technology:JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... year end; no equity financings expected in 2008, ... continue in,2008; latest data for all programs to be ... Expansion of research and development investment in pharmacological, ... 2008, CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
... CALGARY, Jan. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech ... granted Canadian Patent,2,408,251 entitled "Clearance of Neoplastic ... claims describe methods of selectively,removing cancer cells ... other organs using,various viruses including modified vaccinia ...
... MINNEAPOLIS, Jan. 29 Techne Corporation,s,(Nasdaq: TECH ) ... increased 26.7% to $23.6 million or $.60 per diluted ... for the quarter ended December,31, 2006. For the six ... 22.0% to $46.7 million or $1.18 per diluted share,compared ...
Cached Biology Technology:Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent 2Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 6Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 7
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Virginia Tech,s Advanced Experimental Thermofluid Engineering Research ... professor Pavlos P. Vlachos, professor of mechanical engineering, ... mechanics from the Measurement Science and Technology ... Physics. John J. Charonko, of Blacksburg, ...
... -- Scientists Jingfeng Xiao and Scott Ollinger of the ... Earth, Oceans, and Space (EOS) have received funding from ... of competitively awarded grants for the agency,s new Macrosystems ... quantify continental-scale carbon fluxes or so-called carbon "sources" and ...
... the treeless, flat Prairie, you,d think a city would provide ... and roost in trees and buildings. But researchers at the ... landscape is far from ideal for these animals. "I ... and recent PhD graduate in biological sciences at the University ...
Cached Biology News:Virginia Tech mechanical engineers win measurement science best paper award 2UNH researchers receive grant for pioneering carbon cycle model 2UNH researchers receive grant for pioneering carbon cycle model 3Big city holds empty promise for bats 2
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: